GenoMed, Inc. ("GenoMed") is a next-generation disease management company that uses medical genomics to improve patient outcomes.

GenoMed was founded by Dr. David Moskowitz, a Harvard and Oxford trained physician. His research on the angiotensia
I-Converting enzyme (ACE) gene beginning in 1993 and his laboratory discovery that ACE was a "master" disease gene has led to a spectrum of patent-pending medical treatment protocols. The ACE gene was found to be associated with about 160 common yet serious diseases such as type 2 diabetes, common cancers (except for prostate cancer in Caucasian men) and psychiatric diseases.

Dr. Moskowitz, a nephrologist, is a noted pioneer in the field of medical geonomics and has been recognized for his groundbreaking treatment of diseases associated with the angiotensia I-converting enzyme such as chronic renal failure due to hypertension and type 2 diabetes, and emphysema. Dr. Moskowitz's innovative treatment protocols for viruses, including West Nile virus, avian influenza (bird flu) and SARS are also generating considerable scientific interest.

what is Genomic Medicine
Medical Genomics studies the link between gene and disease. This is a relatively new yet rapidly advancing field of medicine about which, as a patient, you may not have heard before.

Through early diagnosis and preventive treatment protocols, some diseases can be stopped before they occur. In the event that a disease does materialize, medication targeted against the disease-causing genes can be extremely effective at delaying the progression of the disease. Genomics-based treatment can dramatically improve the prognosis and greatly reduce the pain and misery of many illnesses otherwise considered incurable. Some clinical outcomes are clearly better than others.

You can help your physician today by subscribing to the Clinical Outcomes Improvement Program offered exclusively by GenoMed. Fill out the enrollment form and send it to us.